Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy - PubMed (original) (raw)

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

E M Velazquez et al. Metabolism. 1994 May.

Abstract

Using polycystic ovary syndrome (PCOS) as a model of insulin resistance and hyperandrogenism, our specific aim was to assess the effect of Metformin on lipoproteins, sex hormones, gonadotropins, and blood pressure in 26 women with PCOS who were studied at baseline, received Metformin 1.5 g/d for 8 weeks, and were then restudied. None of the women had normal menstrual cycles, 100% had multiple subcapsular follicules by pelvic ultrasound, 90% were hirsute, and 85% had high free testosterone. Comparing post-Metformin versus baseline levels, the Quetelet Index (QI) decreased 1.5% (P = .04) and the waist to hip ratio (WHR) decreased 2.8% (P = .003). After covariance adjusting for changes in the QI and WHR, on Metformin the area under the insulin curve (IA) during oral glucose tolerance testing decreased 35% (P = .04), and the insulin area to glucose area ratio decreased 31% (P = .03). On Metformin, covariance-adjusted systolic blood pressure (SBP) decreased (P = .04) and apo A-1 increased (P = .05). On Metformin, with improvement in insulin sensitivity, there were sharp reductions in covariance-adjusted luteinizing hormone ([LH] P = .0007), total testosterone ([T] P = .0004), free T (P = .0001), androstenedione (P = .002), dehydroepiandrosterone sulfate ([DHEAS] P = .006), and the free androgen index ([FAI] P = .0005), with increments in follicle-stimulating hormone ([FSH] P = .04) and sex hormone-binding globulin ([SHBG] P = .04).(ABSTRACT TRUNCATED AT 250 WORDS)

PubMed Disclaimer

Cited by

ROLE OF INSULIN SENSITIZERS ON CARDIOVASCULAR RISK FACTORS IN POLYCYSTIC OVARIAN SYNDROME: A META-ANALYSIS.
Thethi TK, Katalenich B, Nagireddy P, Chabbra P, Kuhadiya N, Fonseca V. Thethi TK, et al. Endocr Pract. 2015 Jun;21(6):645-67. doi: 10.4158/EP14396.RA. Epub 2015 Feb 25. Endocr Pract. 2015. PMID: 25716630 Free PMC article.
Spontaneous singleton and twin pregnancy in two patients with polycystic ovary syndrome and type 2 diabetes following treatment with metformin combined with rosiglitazone.
Demissie YN, Fiad TM, Klemm K, Twfeeg A, Al-Amoudi A, Meer L, Elhadd TA. Demissie YN, et al. Ann Saudi Med. 2006 Jul-Aug;26(4):296-9. doi: 10.5144/0256-4947.2006.296. Ann Saudi Med. 2006. PMID: 16883081 Free PMC article.
Metformin intake associates with better cognitive function in patients with Huntington's disease.
Hervás D, Fornés-Ferrer V, Gómez-Escribano AP, Sequedo MD, Peiró C, Millán JM, Vázquez-Manrique RP. Hervás D, et al. PLoS One. 2017 Jun 20;12(6):e0179283. doi: 10.1371/journal.pone.0179283. eCollection 2017. PLoS One. 2017. PMID: 28632780 Free PMC article.
Evidence for insulin suppression of baseline luteinizing hormone in women with polycystic ovarian syndrome and normal women.
Lawson MA, Jain S, Sun S, Patel K, Malcolm PJ, Chang RJ. Lawson MA, et al. J Clin Endocrinol Metab. 2008 Jun;93(6):2089-96. doi: 10.1210/jc.2007-2656. Epub 2008 Mar 11. J Clin Endocrinol Metab. 2008. PMID: 18334581 Free PMC article. Clinical Trial.
Changes in peripheral mitochondrial DNA copy number in metformin-treated women with polycystic ovary syndrome: a longitudinal study.
Yang PK, Chou CH, Chang CH, Chen SU, Ho HN, Chen MJ. Yang PK, et al. Reprod Biol Endocrinol. 2020 Jul 13;18(1):69. doi: 10.1186/s12958-020-00629-5. Reprod Biol Endocrinol. 2020. PMID: 32660613 Free PMC article. Clinical Trial.

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy - PubMed (original) (raw)